Skip to content
Search for:
COMPANY
SCIENTIFIC APPROACH
PIPELINE
PATIENTS
CAREERS
INVESTORS & MEDIA
CONTACT
Company
cyteir
2022-05-18T10:17:25-04:00
Company
Cancer’s Vulnerability is Our Strength
MANAGEMENT
Markus Renschler, MD
President & Chief Executive Officer
Adam Veness, Esq.
General Counsel
Judson Englert, MD, PhD
SVP, Clinical Research & Development
Jean-Marc Lapierre, PhD
SVP, Chemistry
Andrew Gengos
Chief Business Officer
Gale Cohen
VP, Human Resources
David Gaiero
VP, Finance
Krisztina Nemenyi, PhD, RAC
SVP, Regulatory Affairs and Quality
Paul Secrist, PhD
Chief Scientific Officer
Susan Doleman
VP, Clinical Operations
Lisa Hayes
VP, Investor Relations and Corporate Communications
Tom O'Shea, PhD
SVP, Clinical Pharmacology and Preclinical Development
BOARD OF DIRECTORS
Joseph S. Zakrzewski
Independent Investor & Chairman, Cyteir Therapeutics
Jeffrey Humphrey, MD
Magenta Therapeutics
Markus Renschler, MD
President & Chief Executive Officer
John Thero
Board of Directors at CinCor Pharma
Racquel Bracken
Venrock
Susan Molineaux, PhD
President and CEO of Calithera Biosciences
Timothy Romberger
Founder Cyteir Therapeutics & TRC Advisory
Jean George, MBA
Lightstone Ventures
Janwillem Naesens, MSc, MBA
DROIA
Stephen Sands
Vice Chairman Investment Banking and Chairman of Global Healthcare Group, Lazard
Go to Top